CRISPR Remission for Complex Regional Pain Syndrome (CRPS) : A Flare-Aware Gene Editing Framework

This paper is part of CYNAERA’s CRISPR Remission™ Library, a growing body of work focused on flare-aware, state-dependent gene editing across chronic and neuroimmune conditions.

By Cynthia Adinig

Executive Summary

CRISPR Remission™ introduces a state-dependent, flare-aware gene editing framework for Complex Regional Pain Syndrome (CRPS), a chronic neuroimmune condition characterized by instability across pain, immune, and autonomic systems. This paper explores how CRISPR-based gene regulation may enable durable remission in CRPS by aligning intervention with biological state rather than static treatment models.

Complex Regional Pain Syndrome (CRPS) is still widely approached as a disorder of pain. That framing has limited both treatment outcomes and therapeutic innovation. CRPS is more accurately understood as a condition of multi-system biological instability, in which nociceptive signaling, immune activity, autonomic regulation, and central processing interact in ways that prevent the system from returning to baseline following disruption (Birklein & Schlereth, 2015; Bruehl, 2015).

This instability explains a central clinical pattern. Patients experience cycles of partial improvement and relapse rather than durable recovery. Current treatment strategies, including pharmacologic, interventional, and rehabilitative approaches, can reduce symptoms but rarely restore system-level stability. These approaches are largely state-agnostic, applied without accounting for the dynamic nature of the disease (Birklein et al., 2018; Marinus et al., 2011).

At the same time, the therapeutic landscape is shifting. Advances in gene therapy and CRISPR-based technologies have demonstrated that sustained modulation of disease-relevant pathways is achievable, including long-lasting analgesia through targeted repression of nociceptive channels such as NaV1.7 (Moreno et al., 2021; Chen et al., 2024). More recently, patient-specific in vivo gene-editing therapies have been successfully designed, approved, and administered within clinical settings, establishing the feasibility of customized genomic intervention in human patients (Musunuru et al., 2025).

These developments mark a transition from theoretical capability to practical implementation. However, they also expose a new limitation. Current gene-based approaches are primarily designed for genetically defined and biologically stable conditions, while CRPS is defined by heterogeneity, multi-system interaction, and temporal fluctuation. CRPS is influenced not only by internal neuroimmune dysfunction, but by environmental exposures including air quality, mold, and chemical triggers that can shift system state and alter treatment response. The challenge is no longer whether gene editing can be performed, but how it can be applied effectively within a dynamic system.

CRISPR Remission™, is the AI-powered modeling logic underlying this framework, including the PAMmla algorithm and STAIR Stable Method™, is fully specified in a companion white paper, A Nobel-Scale Advance: AI-Powered CRISPR Platform to End Infection-Associated Chronic Conditions (Adinig, 2025), which provides the technical foundation for terrain-based gene editing across infection-associated chronic conditions. The core CRISPR Remission™ framework has been accepted for presentation at CRISPRMED26 in Copenhagen, underscoring growing recognition of the need for flare-aware, state-dependent approaches in gene editing for complex neuroimmune conditions.

The framework integrates phenotype stratification, target class selection, modality selection across gene regulation strategies, and flare-aware timing, recognizing that intervention success depends on the biological state of the system at the time of treatment. The objective is not temporary analgesia. The objective is durable system stabilization. CRPS does not require stronger suppression.  It requires precision intervention aligned with system dynamics.

1. CRPS as a Multi-System Instability Condition

Complex Regional Pain Syndrome (CRPS) has long occupied an uncertain position within medicine, existing at the intersection of neurology, immunology, and pain management without being fully defined by any single discipline. This ambiguity has shaped a treatment landscape that remains fragmented, where interventions are typically directed toward isolated symptoms rather than the system from which those symptoms emerge. Although CRPS is often introduced as a chronic pain condition following injury, that framing fails to capture the broader biological reality observed in patients. The condition is more accurately understood as a disruption in the body’s ability to return to baseline following physiologic stress, resulting in persistent instability across multiple interacting systems (Marinus et al., 2011; Baron et al., 2010; Birklein & Schlereth, 2015).

Patients with CRPS experience a constellation of symptoms that extend well beyond pain, including swelling, temperature and color asymmetry, motor dysfunction, and evolving sensory abnormalities. These features do not remain static. They fluctuate in response to internal and external stressors, including environmental exposures, immune activation, and physiologic strain. This pattern suggests that CRPS is defined not only by its symptoms, but by the instability underlying them. That instability reflects a breakdown in coordination between peripheral nerve signaling, immune activity, autonomic regulation, and central processing, each of which contributes to the persistence and amplification of symptoms (Bruehl, 2015; Ji et al., 2018; Birklein et al., 2018).

At the peripheral level, CRPS involves sensitization of nociceptive pathways, including altered ion channel activity and increased responsiveness of primary afferent neurons. These changes contribute to hyperalgesia and allodynia, yet they do not fully explain the persistence, spread, or variability of the condition. Inflammatory signaling adds a critical layer, with elevated cytokines and neuroimmune interactions sustaining tissue sensitivity and reinforcing pain pathways. At the same time, autonomic dysfunction alters blood flow, temperature regulation, and vascular tone, directly shaping the tissue environment in which these processes occur. Central sensitization further compounds the condition by amplifying pain processing within the spinal cord and brain, allowing symptoms to persist even in the absence of ongoing peripheral injury (Latremoliere & Woolf, 2009; Ji et al., 2018; Birklein & Dimova, 2017).

These systems do not operate independently. They form a network of feedback loops in which changes in one domain influence behavior in others. Inflammation can increase neural excitability, autonomic instability can alter tissue perfusion and immune signaling, and central sensitization can reinforce peripheral inputs. The result is a condition that is not only multifactorial, but dynamically self-reinforcing. This interconnected structure helps explain why CRPS is difficult to treat using approaches that target a single pathway or mechanism in isolation (Baron et al., 2010; Birklein et al., 2018).

Emerging evidence also supports the role of immune-mediated and genetic susceptibility. Passive transfer studies using patient-derived immunoglobulin G have reproduced CRPS-like features in animal models, indicating that circulating immune factors contribute to disease expression. Genetic analyses have identified rare variants in pathways related to inflammation, macrophage activity, and neuroimmune signaling, suggesting that some individuals may be predisposed to exaggerated or prolonged responses following injury or physiologic stress (Goebel et al., 2010; van Velzen et al., 2019).

This heterogeneity has direct implications for treatment. Patients do not share a uniform biological profile, and the relative contribution of inflammatory, autonomic, neural, and immune mechanisms can vary across individuals and shift over time within the same individual. As a result, interventions that assume biological consistency are unlikely to produce durable outcomes. This pattern of partial response and relapse reflects not only the limits of available therapies, but the absence of frameworks capable of modeling and responding to system-level instability.

CRISPR Remission for CRPS represents a shift from symptom suppression toward system-level stabilization. Recent advances in gene therapy and CRISPR-based technologies introduce a new dimension to this landscape. Preclinical work has demonstrated that targeted modulation of nociceptive pathways, including repression of sodium channels such as NaV1.7, can produce sustained reductions in pain behavior, indicating that long-lasting biological intervention is achievable (Moreno et al., 2021; Chen et al., 2024). More recently, patient-specific in vivo gene-editing therapies have been successfully developed and administered within clinical settings, demonstrating that customized genomic intervention can be designed and delivered in real time (Musunuru et al., 2025).

These developments mark a transition from theoretical capability to clinical feasibility. However, current implementations remain largely focused on genetically defined and relatively stable disease models. CRPS does not fit this profile. It is defined by multi-system interaction, biological variability, and temporal fluctuation. In this context, the central challenge is no longer whether gene editing can be performed, but how it can be applied within a dynamic system.

This paper addresses that gap by introducing a framework for applying gene-based intervention in conditions characterized by instability. This approach aligns with broader CYNAERA modeling systems, including the IACC Twin™ digital twin framework and SymCas™ symptom modeling, which are designed to capture multi-system interaction and state-dependent disease behavior. Within this paradigm, CRPS is not simply a condition that persists. It is a condition that fails to stabilize, and effective intervention must therefore restore the system’s capacity for equilibrium rather than suppress individual outputs.

2. Why Current CRPS Treatments Fail to Produce Remission

Treatment approaches for CRPS reflect the fragmented way the condition has historically been understood. In most cases, patients are managed through combinations of pharmacologic therapies, interventional procedures, and rehabilitation strategies, with each modality targeting a different component of the condition while rarely addressing the broader system in which those components interact. Medications such as neuropathic agents, corticosteroids, and anti-inflammatory therapies can reduce symptom severity, but they frequently fail to produce sustained improvement. Many patients experience diminishing efficacy over time, suggesting that while symptoms may be temporarily reduced, the underlying drivers of the condition remain active (Bruehl, 2015; Baron et al., 2010; Birklein et al., 2018).

Procedural interventions reflect a similar limitation. Nerve blocks and spinal cord stimulation can interrupt pain signaling and provide relief for some patients, yet outcomes remain variable and often difficult to sustain. These approaches primarily modulate downstream signaling pathways without consistently addressing upstream drivers such as immune activation, inflammatory signaling, or autonomic dysregulation. As a result, the system may continue to generate conditions that re-amplify symptoms even after temporary improvement (Kemler et al., 2000; Deer et al., 2017; Fields, 2018).

Rehabilitation remains an essential component of care, particularly for preserving mobility and preventing functional decline. However, its effectiveness is frequently constrained by the biology of the disease itself. Patients may be unable to tolerate the level of activity required for meaningful recovery, especially during periods of flare or physiologic instability. This creates a feedback loop in which limited tolerance restricts rehabilitation, and limited rehabilitation contributes to further dysfunction (Marinus et al., 2011; Ji et al., 2018).

Across these approaches, a consistent pattern emerges. Treatment effects are often partial, improvements are frequently temporary, and relapse remains common. These outcomes are not solely the result of inadequate therapies. More fundamentally, they reflect a mismatch between the dynamic behavior of CRPS and the static design of most current interventions. CRPS operates as a fluctuating system, characterized by shifts in inflammatory activity, autonomic tone, and neural sensitivity, yet most treatments are applied as though the disease were stable and uniform across time.

Recent advances in gene therapy and CRISPR-based approaches suggest that more durable intervention may be possible through targeted modulation of disease-relevant pathways. Preclinical studies demonstrating sustained reductions in pain behavior through repression of channels such as NaV1.7 support the idea that long-term biological modulation is achievable (Moreno et al., 2021; Chen et al., 2024). However, these approaches remain largely focused on individual targets and do not fully account for the multi-system nature of CRPS.

CRPS is not organized around a single pathway. It reflects interaction across neural, immune, and autonomic systems, along with meaningful variability across patients and fluctuation over time. Addressing one pathway in isolation, even with advanced tools, is unlikely to produce consistent remission in a system defined by interaction and instability. A different model is therefore required. One that accounts for heterogeneity in biological drivers, interaction between systems, and the timing of intervention relative to disease state. This shift aligns with CYNAERA frameworks such as SymCas™ and VitalGuard™, which emphasize temporal patterning and environmental influence in disease behavior. Without this broader perspective, even the most advanced therapeutic technologies risk being applied within the same conceptual limitations that have constrained prior treatment strategies.

3. Interacting Biological Systems in CRPS

CRPS cannot be reduced to a single biological mechanism without losing explanatory power. The condition is more accurately understood as a breakdown in coordination across multiple systems that no longer regulate one another effectively. Peripheral nerve activity, immune signaling, autonomic control, and central pain processing do not function independently in CRPS. Instead, they interact through reinforcing feedback loops that sustain and amplify disease activity over time, which helps explain why symptoms often shift in intensity, location, and character rather than remaining fixed or predictable (Birklein & Schlereth, 2015; Bruehl, 2015).

Several biological domains appear to play central and overlapping roles in this process:

• Peripheral nociceptive sensitization, including altered function of primary afferent neurons and ion channels involved in pain transmission

• Inflammatory and neuroimmune signaling, including elevated cytokines that amplify both immune and neural responses

• Autonomic dysfunction, affecting blood flow, temperature regulation, sweating, and local tissue environment

• Central sensitization, in which spinal and cortical pain processing become persistently altered

• Immune-mediated and genetic susceptibility, which may shape how strongly or persistently the system reacts following injury

At the level of peripheral nociception, CRPS involves heightened sensitivity of primary afferent neurons, including altered expression and function of ion channels such as voltage-gated sodium channels and transient receptor potential channels. These changes contribute to exaggerated responses to normally non-painful stimuli and sustained pain signaling following relatively minor triggers. However, nociceptor sensitization alone does not adequately explain the persistence, spread, or migration of symptoms, particularly in cases where pain extends beyond the original site of injury or becomes bilateral over time (Bruehl, 2015; Birklein et al., 2018).

Inflammatory signaling plays a central role in sustaining this sensitized state. Elevated levels of pro-inflammatory cytokines, including interleukin-6 and tumor necrosis factor-alpha, have been observed in affected tissues and circulation, and these molecules influence both immune cell behavior and neuronal excitability. In CRPS, the relationship between inflammation and pain appears to become self-reinforcing, with inflammation increasing neural sensitivity and neural activity further promoting inflammatory signaling. The presence of neurogenic inflammation, in which nerve fibers themselves contribute to inflammatory processes, adds another layer of complexity to this interaction and helps explain why symptoms can escalate even in the absence of major new injury (Birklein & Dimova, 2017; Bruehl, 2015).

Autonomic dysfunction introduces another major source of instability. Patients frequently exhibit abnormalities in vasoconstriction and vasodilation, temperature regulation, and sweating, reflecting dysregulation of sympathetic nervous system activity. These disturbances can alter tissue oxygenation, metabolic demand, and local inflammatory responses, all of which influence symptom severity and variability. The autonomic system is therefore not a passive background feature of CRPS. It actively shapes the disease environment and contributes to the persistence of both neural and immune dysregulation (Marinus et al., 2011; Birklein & Schlereth, 2015).

Central sensitization further reinforces the condition by altering pain processing at the spinal and cortical levels. Over time, the central nervous system may amplify incoming signals or generate pain in the absence of ongoing peripheral input, reducing the system’s ability to return to baseline following a trigger. These central changes do not occur in isolation. They are influenced by continuing peripheral sensitization, inflammatory signaling, and autonomic disturbance, creating a continuous loop of reinforcement that helps account for the chronicity and unpredictability of the condition (Bruehl, 2015; Birklein et al., 2018).

Emerging evidence also supports the involvement of immune-mediated and genetic factors in shaping disease expression. Passive transfer studies have shown that immunoglobulin G from CRPS patients can induce symptoms in animal models, suggesting that circulating immune factors contribute to the condition. Genetic analyses have further identified rare variants in genes associated with inflammatory signaling, macrophage activity, and neuroimmune regulation, indicating that some individuals may be biologically predisposed to exaggerated or prolonged responses following injury or physiologic stress (Goebel et al., 2010; van Velzen et al., 2019). These findings reinforce the idea that CRPS is not purely reactive, but may also be partially structured by underlying susceptibility.

Taken together, CRPS can be understood as a condition in which multiple regulatory systems fail to return to equilibrium after disruption. Peripheral sensitization, inflammation, autonomic dysfunction, central sensitization, and biologic susceptibility do not act as isolated drivers. They form an interconnected network that sustains instability over time. Any intervention that targets only one component without accounting for this broader network is likely to produce incomplete or temporary effects.

4. Genetic Susceptibility and Neuroimmune Drivers in CRPS

The variability observed in CRPS is not random. Differences in symptom presentation, progression, and treatment response suggest that patients do not share a uniform biological profile, but instead reflect a spectrum of underlying susceptibilities that influence how the condition develops and persists. This variability has important implications for treatment, particularly when the goal shifts from temporary symptom reduction to durable system-level change.

Genetic studies provide some of the clearest evidence that CRPS includes a measurable susceptibility component. Analyses of chronic CRPS populations have identified rare variants in genes such as ANO10, P2RX7, PRKAG1, and SLC12A9, many of which are expressed in immune cells and involved in ion transport, inflammatory signaling, and cellular energy regulation. These pathways intersect directly with mechanisms implicated in CRPS, including neuroinflammation, nociceptive sensitization, and immune activation (van Velzen et al., 2019; Ji et al., 2018). The presence of these variants suggests that some individuals may be predisposed to exaggerated or prolonged responses following injury or physiologic stress rather than simply reacting proportionally to the initiating event.

Among these, P2RX7 is particularly notable due to its role in purinergic signaling and immune activation. This receptor is involved in ATP-mediated signaling, cytokine release, and macrophage activation, and has been linked to both pain amplification and neuroimmune interaction. Its identification in CRPS reinforces the convergence between inflammatory and nociceptive pathways, highlighting that pain in this condition is not purely neuronal but embedded within broader immune signaling networks (Baron et al., 2010; Birklein & Dimova, 2017).

Genetic susceptibility, however, does not act independently. It interacts with environmental exposures, infectious triggers, and physiologic stress to shape disease expression over time. This interaction helps explain why similar injuries can result in vastly different outcomes across individuals and why CRPS may evolve rather than remain biologically static. In this sense, susceptibility modifies system behavior, influencing both the intensity of response and the system’s ability to return to baseline.

Molecular heterogeneity further complicates this picture. In some patients, inflammatory signaling appears to dominate, with elevated cytokines sustaining symptom expression. In others, autonomic dysfunction or peripheral nerve sensitization may be more prominent. Still others exhibit features consistent with immune-mediated processes, including circulating antibodies capable of altering neural signaling. These patterns are not always clearly delineated in clinical practice, yet they have substantial implications for treatment response and durability (Goebel et al., 2010; Bruehl, 2015; Ji et al., 2018).

This pattern of variability is not unique to CRPS. Similar dynamics have been described across other complex conditions involving immune and metabolic dysregulation, where genetic predisposition interacts with environmental and physiologic stressors to produce heterogeneous outcomes. CYNAERA analyses in areas such as in the Enhancing CRISPR Safety in Sickle Cell Disease white paper, have similarly identified that disease expression is shaped not only by primary pathology, but by system-level interaction and susceptibility layering. These parallels reinforce that variability is not an anomaly but a defining feature of complex disease systems. Taken together, these findings support a central conclusion. CRPS cannot be effectively treated through uniform intervention strategies. Approaches that assume biological homogeneity are likely to produce inconsistent outcomes in a condition defined by variability and instability. Precision intervention is therefore not optional. It is structurally required.

5. CRISPR and Gene Regulation in Chronic Pain Systems

The emergence of gene therapy and CRISPR-based technologies has introduced a fundamentally different category of intervention in chronic pain research. Unlike traditional therapies that modulate signaling pathways transiently, these approaches aim to produce sustained changes at the molecular level, altering the behavior of cells and circuits involved in pain processing.

Early gene therapy efforts in pain explored a range of delivery systems, including adeno-associated viruses, herpes simplex virus vectors, and RNA-based strategies such as small interfering RNA and antisense oligonucleotides. These approaches targeted dorsal root ganglia, spinal pathways, and peripheral tissues with the goal of modifying nociceptive signaling at its source. Advances in vector engineering and tissue targeting have improved the precision of these interventions, allowing for more selective modulation of pain-relevant pathways (Habib et al., 2023; Chen et al., 2024).

CRISPR-based technologies extend this capability by enabling direct and programmable control over gene expression. Different modalities offer different levels of intervention, from permanent sequence editing using CRISPR-Cas9 to reversible gene regulation through CRISPR interference and activation systems. Base editing and prime editing further expand this range by allowing targeted modification without inducing double-strand breaks, increasing both precision and potential safety (Chen et al., 2024; Doudna, 2020).

Preclinical studies have demonstrated that these approaches can produce sustained changes in pain behavior. Targeted repression of NaV1.7 has resulted in long-lasting reductions in hyperalgesia and allodynia across multiple models of inflammatory and neuropathic pain, without impairing normal motor function. These findings indicate that selective modulation of nociceptive pathways is possible without disrupting essential neural processes (Moreno et al., 2021; Waxman, 2013). Similar work targeting TRPV1 and related channels further supports the potential for gene-based approaches to influence chronic pain at its source rather than through downstream suppression.

At the same time, the field remains in an early stage of clinical translation. Challenges related to delivery precision, off-target effects, immune response, and long-term safety continue to shape development. No gene therapy has yet been approved specifically for chronic pain, and clinical application remains limited. These constraints highlight the need for careful system-level design, particularly in conditions such as CRPS that are defined by multi-system interaction rather than single-pathway dysfunction (Habib et al., 2023; Chen et al., 2024).

The translational landscape has shifted further with the emergence of patient-specific, in vivo gene-editing approaches. Recent clinical work has demonstrated that customized base-editing systems can be rapidly designed, validated, and delivered under regulatory approval for a single patient, resulting in measurable clinical improvement without serious short-term adverse events (Musunuru et al., 2025). This establishes a precedent for real-time, individualized genomic intervention and signals that gene editing is no longer constrained to theoretical or preclinical contexts.

This shift has important implications for chronic pain and neuroimmune conditions. While CRPS is not driven by a single monogenic mutation, the feasibility of designing patient-specific interventions demonstrates that the primary limitation is no longer technical capability. Instead, the challenge lies in determining which targets to modulate, in which patients, and under what biological conditions.

This same principle has emerged in CYNAERA analyses of gene-based intervention across other disease states. Work examining CRISPR safety and targeting strategies, such as in CYNAERA’s CRISPR Cell Therapy for Type 1 Diabetes white paper, highlights that successful gene-based intervention depends not only on identifying the correct target, but on understanding how that target behaves within a dynamic, multi-system environment. These findings reinforce that gene editing, when applied without system-level context, risks reproducing the same limitations seen in traditional therapies. In this context, CRISPR-based approaches transition from experimental tools to deployable therapeutic platforms. Their effectiveness in CRPS will depend not only on molecular precision, but on the ability to integrate target selection, patient phenotype, and system state into a coordinated intervention strategy.

6. Why Pain Treatments Fail in CRPS & Why Remission Requires a Different Model

Recent advances in gene therapy and CRISPR-based technologies have demonstrated that targeted modulation of nociceptive pathways can produce sustained reductions in pain behavior in preclinical models. This marks a meaningful departure from traditional pharmacologic strategies, which often require continuous administration, show variable efficacy across patients, and frequently lose effectiveness over time. The fact that long-lasting analgesia can now be achieved through molecular intervention suggests that durable change within pain systems is biologically possible (Moreno et al., 2021; Chen et al., 2024).

Even so, most current approaches remain framed around analgesia, or the reduction of pain signaling. While that is an important therapeutic goal, it does not fully address the complexity of conditions such as CRPS. Analgesia focuses on dampening output within a system, whereas CRPS reflects dysfunction within the system itself. As a result, interventions that successfully reduce nociceptive signaling may still leave broader biological instability intact, particularly when inflammatory, autonomic, and central mechanisms continue to reinforce one another.

This distinction becomes clearer when the architecture of CRPS is considered directly. The condition is shaped by interacting domains that include peripheral sensitization, inflammatory signaling, autonomic dysregulation, and altered central processing. These layers do not operate in isolation, and the behavior of one can alter the behavior of others. A reduction in nociceptive signaling may lower pain intensity, but it does not necessarily resolve underlying immune activation, autonomic instability, or central sensitization. This helps explain why some patients improve partially without achieving durable remission, and why symptoms often re-emerge under physiologic stress, environmental exposure, or other destabilizing conditions (Birklein & Dimova, 2017; Bruehl, 2015).

The contrast between analgesia and remission is therefore not semantic. It reflects two fundamentally different treatment goals:

• Analgesia aims to reduce pain signaling and symptom burden

• Remission aims to restore the system’s ability to maintain equilibrium over time

• Analgesia can occur even when core disease drivers remain active

• Remission requires reduction of the processes that generate and sustain instability

This difference is especially important in CRPS, where temporary pain reduction does not necessarily indicate meaningful biologic recovery. Current CRISPR-based approaches in pain research have largely focused on individual targets, such as NaV1.7, in order to reduce nociceptive activity. These studies are important because they establish proof of concept for sustained molecular intervention. However, they do not account for the heterogeneity of CRPS or the fact that the relative contribution of inflammatory, autonomic, neural, and immune mechanisms can vary substantially across patients and even shift over time within the same patient (van Velzen et al., 2019; Birklein et al., 2018).

Timing further complicates this picture. CRPS symptoms often fluctuate between periods of relative stability and periods of exacerbation, yet intervention strategies are rarely designed around those fluctuations. Treatment delivered during periods of heightened instability may encounter amplified immune signaling, altered tissue environments, or intensified neural sensitivity, all of which may reduce effectiveness or increase risk. By contrast, periods of relative stability may offer a more favorable biological context for intervention, but these state-dependent dynamics are not typically incorporated into treatment design.

These limitations do not diminish the significance of CRISPR-based advances. If anything, they make the field’s next challenge more visible. The issue is no longer whether molecular tools can produce long-lasting analgesia. It is whether those tools can be applied in a way that reflects the biology of unstable, multi-system conditions. Moving from analgesia to remission therefore requires a shift in perspective, from treating pain as an isolated output to treating CRPS as a dynamic disease state requiring coordinated, state-aware intervention.

7. CRISPR Remission™ Framework

CRISPR Remission™ is proposed as a framework for applying gene-based intervention in conditions characterized by biological instability, with CRPS serving as a primary use case. Rather than focusing on a single target or modality, the framework is organized around decision layers that reflect the complexity of the disease itself. These layers include phenotype stratification, target class selection, modality selection, and timing, each of which contributes to the likelihood of achieving durable system stabilization.

Phenotype stratification represents the first layer of the framework. CRPS patients do not present with uniform biological profiles, and differences in symptom expression often reflect differences in underlying mechanisms. Some patients exhibit features more consistent with inflammatory dominance, including elevated cytokines, edema, and tissue-level inflammatory activity. Others show more prominent autonomic dysfunction, with significant changes in blood flow, temperature regulation, and vascular tone. Additional subgroups may be characterized by peripheral nerve sensitization, immune-mediated mechanisms, or post-infectious amplification, where systemic instability follows infection or other broader physiologic disruption. These distinctions are not merely descriptive. They shape which pathways are most relevant for intervention and help determine why patients respond differently to similar treatments (Marinus et al., 2011; Bruehl, 2015; Birklein & Dimova, 2017; van Velzen et al., 2019).

Target class selection follows from phenotype stratification. Instead of reducing intervention to a single gene, the framework organizes potential targets into functional categories that correspond to the major systems involved in CRPS. These categories include nociceptive signaling pathways, such as voltage-gated sodium channels and transient receptor potential channels; inflammatory pathways involving cytokines, chemokines, and immune signaling molecules; purinergic signaling pathways, including receptors such as P2RX7; and regulators of glial activation and central pain amplification. Framing targets this way supports a more flexible and biologically coherent intervention strategy, particularly in a condition where peripheral sensitization, neuroinflammation, and central sensitization frequently overlap rather than appearing in isolation (Baron et al., 2010; Ji et al., 2018; Moreno et al., 2021; van Velzen et al., 2019).

Modality selection represents the third layer. CRISPR-based technologies now offer a range of intervention options, from permanent editing of genetic sequences to reversible modulation of gene expression through CRISPR interference and CRISPR activation. The most appropriate modality depends on the role of the target within the broader system, the desired duration of effect, and the safety implications of altering that pathway. In pain systems, where complete elimination of signaling is neither desirable nor physiologically appropriate, approaches that allow partial or reversible modulation may offer a more balanced strategy. This is particularly relevant in CRPS, where the problem is not the existence of pain signaling itself, but the persistence of maladaptive amplification across multiple systems (Chen et al., 2024; Moreno et al., 2021; Habib et al., 2023).

Timing introduces a critical dimension that remains largely underdeveloped in most treatment models. CRPS is characterized by fluctuations in disease activity, with periods of increased inflammation, autonomic instability, and neural sensitization followed by narrower intervals of relative stabilization. Intervening during periods of heightened instability may reduce the effectiveness of treatment or increase the risk of adverse outcomes, whereas periods of lower volatility may provide a more favorable biological context for intervention. The CRISPR Remission™ framework therefore incorporates the concept of stabilization windows, defined as periods in which the system is more likely to tolerate and respond to targeted modulation. Identifying these windows requires integration of clinical observation, symptom tracking, and, where possible, biomarker and physiologic data rather than relying on static treatment schedules alone (Marinus et al., 2011; Fields, 2018; Ji et al., 2018).

The final layer of the framework involves integration across systems. Gene-based intervention is not positioned as a standalone solution, but as one component of a broader strategy that may also include environmental control, autonomic stabilization, and immune modulation. This reflects the biological reality of CRPS, which is maintained by interaction across systems rather than by a single dominant lesion. Taken together, these layers form a decision architecture rather than a one-size-fits-all treatment protocol. The objective is not to apply CRISPR uniformly, but to apply it strategically in a way that reflects the biological state of the patient and the dynamics of the disease over time.

8. Post-Infectious Amplification in CRPS

Clinical observations increasingly suggest that CRPS can change in character following infection, particularly in the context of systemic illnesses such as COVID-19. Patients with previously stable or more localized CRPS may develop new features, including broader distribution of pain, increased environmental sensitivity, worsening autonomic instability, and symptoms suggestive of mast cell activation or broader immune dysregulation. These changes imply not simply worsening, but a shift in the biological architecture of the condition from a more localized pain disorder toward a more systemic and reactive phenotype.

This pattern aligns with broader findings from post-infectious illness research, where immune dysregulation, endothelial dysfunction, autonomic disturbance, and prolonged inflammatory signaling can persist well beyond the acute phase of infection. In that setting, pre-existing vulnerabilities may become amplified, pushing patients into more complex and less predictable symptom states. CRPS, given its established interaction between neural, immune, and autonomic systems, appears particularly vulnerable to this kind of amplification rather than remaining biologically contained (Ji et al., 2018; Birklein & Schlereth, 2015; Baron et al., 2010).

The concept of post-infectious amplification offers a more useful framework than simply describing these cases as more severe. It suggests a shift in the relative contribution of disease drivers, with systemic inflammation, immune activation, endothelial stress, and autonomic dysfunction taking on greater influence over symptom expression. That shift may alter both the clinical picture and the logic of treatment, since interventions that once worked in a more localized phenotype may become less effective when the condition is being sustained by broader neuroimmune instability. Seen this way, infection does not merely worsen CRPS. It may restructure it.

Environmental exposures may deepen this restructuring further. Mold, particulate exposure, and poor air quality have all been associated with increased immune activation and symptom worsening in susceptible populations, particularly in conditions where inflammatory and autonomic systems are already unstable. In patients with CRPS, these factors may interact with existing vulnerabilities and increase flare frequency, intensity, or duration, creating a phenotype that is more reactive to the environment and more difficult to stabilize through conventional approaches alone.

Recognizing post-infectious amplification has implications for both classification and treatment. It suggests that CRPS should not always be treated as a single condition with a fixed trajectory, but as a spectrum that may include subtypes shaped by additional systemic pressures. Within the CRISPR Remission™ framework, post-infectious CRPS represents a phenotype in which immune and autonomic pathways may carry greater weight in target selection, timing, and integration strategy. Understanding this subtype is not only clinically useful. It also provides a broader window into how CRPS interacts with neuroimmune instability across chronic and post-infectious disease states.

9. Modeling CRPS Remission Using Flare-Aware Intervention

To illustrate how CRISPR Remission™ functions in practice, a modeled case is presented reflecting a patient with chronic CRPS characterized by multi-system instability. The objective of this model is not to demonstrate symptom suppression in isolation, but to show how coordinated, phenotype-specific intervention can shift the system toward a more stable equilibrium. The modeled patient presents with a four-year history of CRPS following injury, with a relapsing-remitting symptom pattern marked by frequent flare cycles. Clinical features include persistent allodynia and hyperalgesia, temperature asymmetry, vascular instability, and elevated inflammatory markers. Symptom tracking further reveals sensitivity to environmental factors, with flare severity increasing in response to humidity changes and poor air quality. This pattern is consistent with a system in which neural, immune, and autonomic processes are interacting in a self-reinforcing manner rather than resolving over time.

Step 1: Phenotype Stratification

The patient is classified as a mixed inflammatory-autonomic CRPS phenotype with secondary nociceptive amplification.

Primary system drivers include:

• inflammatory signaling

• autonomic dysregulation

• nociceptive pathway sensitization

This classification establishes that intervention must target multiple interacting domains rather than a single pathway. In this phenotype, inflammatory and autonomic variability are expected to contribute more heavily to system instability than nociceptive variability alone.

Step 2: Target Class Selection

Intervention targets are grouped by functional role:

• nociceptive signaling → NaV1.7 modulation

• inflammatory signaling → IL-6 pathway regulation

• purinergic signaling → P2RX7-associated immune activation

• autonomic instability → indirect stabilization via upstream modulation

Rather than selecting a single gene, the framework prioritizes coordinated modulation across target classes, reflecting the networked structure of CRPS and the reinforcing relationships between domains.

Step 3: Modality Selection

The selected intervention strategy includes:

• CRISPR interference, or CRISPRi, for reversible repression of NaV1.7

• gene regulation targeting inflammatory signaling pathways

• avoidance of permanent knockout in high-risk pathways

This approach prioritizes modulation over elimination, reducing pathological amplification while preserving essential physiological signaling.

Step 4: Flare-Aware Timing and Stabilization Windows

Symptom tracking identifies a repeating pattern. Flare peaks occur approximately every 5 to 7 days, followed by stabilization periods lasting about 48 to 72 hours. Intervention is therefore scheduled during stabilization windows, defined as periods in which overall system volatility is decreasing across the major interacting domains.

System state is modeled across five variables:

• N(t) = nociceptive signaling

• I(t) = inflammatory load

• A(t) = autonomic instability

• C(t) = central sensitization

• E(t) = environmental or external load

All variables are normalized on a 0 to 10 scale, where 10 represents the highest clinically observed severity.

Stabilization readiness is defined as a weighted inverse function of system volatility:

W(t) is proportional to 1 divided by [alpha × sigma_N + beta × sigma_I + gamma × sigma_A + delta × sigma_C + epsilon × sigma_E]

Or, in compact form:

W(t) ∝ 1 / (alpha·sigma_N + beta·sigma_I + gamma·sigma_A + delta·sigma_C + epsilon·sigma_E)

Where:

• sigma represents short-term variability in each domain

• alpha, beta, gamma, delta, and epsilon represent phenotype-specific weights

In this modeled case, beta and gamma carry the greatest weight because the patient is classified as an inflammatory-autonomic subtype. That means inflammatory volatility and autonomic volatility matter more than the other domains when determining whether the system is ready for intervention.

A stabilization window is defined as any period in which:

• W(t) is greater than a minimum threshold, theta

• dW/dt is less than 0

In plain language, this means the system is not only relatively stable, but is actively moving toward lower volatility rather than toward another flare.

This identifies periods where:

• overall volatility is low

• the system is actively stabilizing rather than destabilizing

Intervention outside this window is associated with reduced efficiency and increased rebound risk.

Step 5: System Dynamics and Modeled Impact

CRPS is modeled as a coupled system in which each major domain reinforces the others over time. Symptom burden is treated as the output of the system rather than the primary driver.

Symptom burden is defined as:

S(t) = w1·N(t) + w2·I(t) + w3·A(t) + w4·C(t)

Where:

• S(t) = total symptom burden

• w1, w2, w3, w4 = weighting factors for each domain

The interaction between domains is represented as follows:

• dN/dt ∝ I + A + C Nociceptive signaling increases as inflammatory load, autonomic instability, and central sensitization increase.

• dI/dt ∝ N + E + A Inflammatory load increases as nociceptive activity, environmental stress, and autonomic instability increase.

• dA/dt ∝ I + E + C Autonomic instability increases as inflammation, environmental load, and central sensitization increase.

• dC/dt ∝ N + I + A Central sensitization increases as nociceptive signaling, inflammatory load, and autonomic instability increase.

This structure reflects a reinforcing-loop model of CRPS in which inflammation amplifies neural sensitivity, autonomic dysfunction alters tissue conditions and stress responses, central sensitization sustains persistence and spread of symptoms, and environmental load acts as an additional destabilizing force.

Modeled System Behavior

Pre-Intervention State

• high variability across domains

• frequent flare spikes

• incomplete return to baseline

Single-Target Intervention, NaV1.7 Only

• reduction in nociceptive signaling

• persistent inflammatory and autonomic activation

• continued system oscillation

Multi-Target Coordinated Intervention

• NaV1.7 + IL-6 + P2RX7 modulation

• reduced cross-system amplification

• improved recovery between flares

• decreased system volatility

Timing Effect

• intervention during high volatility → reduced efficacy and increased rebound

• intervention during stabilization → improved durability and system recovery

Illustrative Simulation Snapshot

Time	N(t)	I(t)	A(t)	C(t)	W(t)	Intervention
Day 1	8	9	8	7	0.03	No, high volatility
Day 4	5	6	5	5	0.07	Borderline
Day 5	4	5	4	4	0.09	Yes, stabilization window
Day 10	3	3	3	3	0.12	Post-intervention stabilization

This simplified simulation demonstrates that intervention timing relative to system volatility alters projected outcomes independently of target selection alone.

Modeled Outcome

The modeled outcome reflects a shift in system behavior rather than elimination of symptoms. Flare amplitude is reduced, stabilization periods are extended, the frequency of exacerbations decreases, and the system shows a stronger recovery trajectory over time. These changes represent movement toward a more stable equilibrium rather than complete suppression of all signaling pathways.

Why This Model Matters

CRPS cannot be stabilized through isolated targeting of a single pathway. Durable improvement requires coordinated modulation across interacting systems, informed by patient-specific biology and applied within the correct temporal context. CRISPR Remission™ functions as a state-aware intervention architecture, aligning gene-based therapies with phenotype, pathway interaction, and system timing. The implications extend beyond CRPS. Conditions characterized by neuroimmune instability and fluctuating disease dynamics share similar structural features, suggesting that this framework may be broadly applicable across chronic disease systems.

10. Translating CRISPR Remission™ into Clinical Practice

The potential of gene-based intervention in CRPS must be considered alongside its risks. Unlike conventional therapies that can be adjusted or discontinued with relative ease, gene-editing and gene-regulatory approaches introduce changes at the molecular level that may persist beyond the intended therapeutic window. This makes precision in target selection, modality, and timing essential not only for efficacy, but for safety.

One of the primary concerns in CRISPR-based approaches is the risk of off-target effects. Unintended edits or regulatory changes in non-target genes can lead to unpredictable outcomes, particularly in complex systems such as the nervous and immune systems. Advances in guide RNA design and delivery methods have reduced this risk, but it remains a critical consideration, especially when targeting pathways that are widely expressed or functionally interconnected (Chen et al., 2024; Habib et al., 2023).

Immunogenicity presents an additional challenge. Both viral vectors used for delivery and components of CRISPR systems themselves can provoke immune responses, potentially limiting effectiveness or introducing adverse effects. This is particularly relevant in CRPS, where immune dysregulation is already present. Introducing additional immune activation into an unstable system may exacerbate symptoms rather than resolve them if not carefully managed (Birklein & Dimova, 2017; Chen et al., 2024). Delivery remains one of the most significant technical barriers. Targeting dorsal root ganglia and peripheral nerve structures requires precise localization, and while intrathecal and viral delivery approaches have shown promise in preclinical studies, translating these methods into safe and scalable clinical applications remains an ongoing challenge. Achieving sufficient specificity without widespread distribution is essential to avoid unintended systemic effects (Moreno et al., 2021; Habib et al., 2023).

The question of permanence versus reversibility is particularly important in pain systems. Complete and irreversible elimination of nociceptive signaling is neither desirable nor safe, as pain serves a protective function. Approaches that allow for partial or reversible modulation, such as CRISPR interference or activation, may offer a more balanced strategy by reducing pathological signaling while preserving baseline function. This distinction is critical when designing interventions intended to restore stability rather than eliminate sensation (Chen et al., 2024; Moreno et al., 2021).

Ethical considerations extend beyond technical risks. Patient selection, informed consent, and equitable access must be addressed, particularly in conditions like CRPS that are often underdiagnosed or inconsistently treated. The introduction of advanced therapies into a fragmented care landscape raises questions about who will have access to these interventions and under what conditions. Ensuring that these technologies do not exacerbate existing disparities is an essential component of responsible development.

A key unresolved challenge in translating gene-based approaches to CRPS is achieving targeted and efficient delivery to dorsal root ganglia and peripheral nerve structures. Current approaches using adeno-associated viral vectors are limited by serotype specificity and variable tropism, while lipid nanoparticle delivery systems, though promising, face challenges in tissue targeting and distribution across affected regions. Given that CRPS often involves distributed peripheral and autonomic networks rather than a single localized target, effective intervention may require advances in region-specific delivery, repeat dosing strategies, or hybrid delivery systems capable of addressing multi-site involvement.

Within the CRISPR Remission™ framework, safety is not treated as a secondary consideration. It is embedded within the decision architecture itself. Phenotype stratification reduces the risk of inappropriate targeting. Modality selection allows for adjustment of intervention intensity and reversibility. Timing considerations help avoid intervention during periods of heightened instability. Together, these elements support a model in which precision functions as both a therapeutic and protective mechanism.

11. Safety, Timing, and Delivery in Gene-Based Intervention

Translating gene-based approaches into clinical practice requires more than technical feasibility. It requires a structured development pathway that can connect biological insight to real-world implementation, while accounting for patient heterogeneity, delivery constraints, and the practical demands of monitoring response over time. In CRPS, this challenge is especially pronounced because the condition does not conform to the assumptions that have traditionally shaped translational medicine. It is neither biologically uniform nor temporally stable, and for that reason the pathway from concept to clinic must be designed with greater flexibility from the outset.

The first stage of translation remains preclinical development, but the limitations of current models are important. Existing inflammatory and neuropathic pain models provide a useful foundation for testing gene-regulatory approaches, yet they do not fully capture the multi-system nature of CRPS. Expanding preclinical work to include models that better reflect neuroimmune interaction, autonomic disturbance, and fluctuating disease states will be essential if remission-oriented strategies are to be evaluated on terms that are relevant to the condition itself. In this context, preclinical success cannot be defined solely by pain reduction. It must also include measurable effects on system stability over time.

Clinical trial design presents a second layer of complexity. Traditional trial structures often assume relatively homogeneous patient populations and disease states that remain sufficiently stable to permit straightforward comparison across treatment arms. CRPS resists both assumptions. Incorporating phenotype stratification into trial design will therefore be necessary to identify which patients are most likely to benefit from particular interventions and to interpret outcomes in a biologically meaningful way. This may involve the use of biomarkers, symptom clustering, and longitudinal disease tracking to support patient selection and response assessment, rather than relying exclusively on static diagnostic categories (van Velzen et al., 2019; Bruehl, 2015).

Delivery strategies must evolve alongside trial design. Intrathecal and targeted delivery to dorsal root ganglia remain among the most promising approaches for pain-relevant gene intervention, but these methods still require refinement to achieve the level of safety, specificity, and scalability that clinical implementation will demand. Advances in vector design, including non-viral delivery systems, may help address some of these limitations by reducing immunogenicity and improving targeting precision, but translation will depend on integrating delivery strategy with the biology of the condition rather than treating it as a purely technical problem (Chen et al., 2024; Habib et al., 2023).

Monitoring and feedback represent another critical and often underdeveloped dimension of translation. In a fluctuating condition such as CRPS, static outcome measures can miss meaningful changes in disease behavior. Effective translation will require a more dynamic monitoring model, one capable of capturing changes in symptom burden, autonomic function, inflammatory activity, and flare timing over time. That kind of feedback is not only useful for measuring treatment response. It is also necessary for refining timing, dosing, and patient selection in future iterations of therapy. Taken together, the translational pathway for CRPS requires coordinated development across several domains:

• Preclinical models that reflect neuroimmune, autonomic, and temporal instability rather than pain signaling alone

• Clinical trial structures that incorporate phenotype stratification and biologically meaningful subgrouping

• Delivery systems capable of achieving precise and scalable targeting with acceptable safety profiles

• Monitoring frameworks that can track disease fluctuation and support state-aware intervention over time

Integration into clinical practice will require coordination across specialties as well. CRPS sits at the intersection of neurology, pain medicine, immunology, and rehabilitation, and gene-based interventions will need to enter this landscape in a way that supports collaboration rather than reproducing the fragmentation that has already limited care. This may ultimately require specialized centers, protocols, or care pathways that bring together expertise from multiple domains and treat biologic instability as a shared clinical problem rather than a disciplinary boundary.

12. Economic Impact and System-Level Value in CRPS

From a commercial standpoint, the implications are substantial. Chronic pain represents a large and expanding market, yet durable treatment options remain limited. A framework that enables precision, remission-oriented intervention has the potential to reshape not only CRPS treatment, but the broader chronic pain landscape as well. The relevance of such a framework may extend to other conditions characterized by neuroimmune instability, including neuropathic pain syndromes, post-infectious conditions, and autonomic disorders, giving it significance beyond a single diagnosis.

The value of the CRISPR Remission™ framework lies not only in its scientific rationale, but in its ability to organize development across these translational stages. By structuring decision-making around patient selection, target identification, modality choice, and timing, the framework creates a pathway from concept to implementation that is both scalable and adaptive. This becomes even more significant in light of recent advances in N-of-1 gene-editing protocols. The rapid development and administration of a patient-specific base-editing therapy, delivered in vivo through lipid nanoparticles under expedited regulatory oversight, demonstrates that the transition from customized genomic intervention to clinical care is now possible within real-world medical systems (Musunuru et al., 2025). That development introduces a new model of translational medicine in which therapies do not have to be designed only for broad populations, but can be tailored to individual patients or highly specific subgroups.

For CRPS, this shift is especially important. The condition is not a monogenic disorder, and its complexity extends well beyond genetic specificity alone. Successful implementation will therefore depend not only on the ability to build customized therapies, but on the ability to determine how those therapies should be configured within a dynamic system, for which patients, and at what biological moment. In that sense, the next barrier to translation is no longer simply technical. It is architectural, requiring frameworks that can align gene-based intervention with phenotype, pathway interaction, and disease-state timing.

The introduction of CRISPR-based and gene-regulatory therapies into chronic pain conditions such as Complex Regional Pain Syndrome (CRPS) has implications that extend beyond clinical efficacy. It alters the economic structure of care in a condition defined by chronicity, relapse, and multi-system instability. CRPS is associated with sustained healthcare utilization, including repeated specialist visits, pharmacologic management, interventional procedures, and rehabilitation services, while indirect costs such as lost productivity and disability further expand total burden.

Published cost analyses provide a clear baseline for understanding this burden. In a large U.S. claims-based study, Zhao et al. (2018) found that median annual total healthcare cost increased from $3,437 three years prior to diagnosis to $8,508 in the diagnosis year, representing an excess of $5,071 per patient. Costs remained elevated at $4,845 in the first post-diagnosis year, or $1,408 above baseline, and patients incurred 2.17 times baseline total costs and 2.56 times baseline pain-related prescription costs during the diagnostic period. These findings reflect not only disease severity, but inefficiencies embedded in the treatment model itself, particularly the repeated application of therapies during periods of biological instability rather than system readiness.

Within the CRISPR Remission™ framework, a meaningful portion of this excess cost can be understood as recoverable. The framework does not assume elimination of disease burden, but instead targets the component of cost driven by misalignment between intervention and system state. This allows economic impact to be modeled using conservative capture rates applied to the excess cost observed in real-world data. Using the Zhao et al. (2018) dataset as a reference point, diagnosis-year excess cost can be expressed as:

Diagnosis-Year Excess Cost = $8,508 − $3,437 = $5,071 per patient

If flare-aware, phenotype-stratified intervention captures only a portion of this excess:

• At 25% capture, direct savings are approximately $1,268 per patient

• At 40% capture, direct savings increase to $2,028 per patient

• At 60% capture, direct savings reach $3,043 per patient

These estimates reflect reduced treatment cycling, fewer ineffective interventions, and improved durability of response rather than complete resolution of disease. A similar model can be applied to ongoing post-diagnosis cost. Using the same study, the persistent annual excess after diagnosis is:

Post-Diagnosis Excess Cost = $4,845 − $3,437 = $1,408 per patient-year

Applying the same conservative capture assumptions yields:

• $352 per patient-year at 25% capture

• $563 per patient-year at 40% capture

• $845 per patient-year at 60% capture

These values reflect reduced long-term utilization driven by fewer flares, decreased escalation of care, and improved stability across interacting systems.

Direct healthcare savings alone do not capture the full economic burden of CRPS. A separate economic analysis by Doth et al. (Pain Medicine, 2013) estimated total annual per-patient cost at $24,043, with more than half attributable to lost productivity, disability, and wage replacement. To remain conservative, a 50% allocation can be used as a floor estimate, yielding a productivity-related burden of approximately $12,021 per patient-year.

If CRISPR Remission™ enables even partial restoration of function, the economic impact becomes substantial. Applying modest recovery assumptions:

• At 10% productivity recovery, indirect savings are approximately $1,202 per patient-year

• At 20%, $2,404 per patient-year

• At 30%, $3,606 per patient-year

These gains reflect increased workforce participation, reduced disability dependence, and improved functional capacity rather than full return to baseline. When direct and indirect effects are combined, the total economic value becomes more apparent. In the diagnosis year, the combined impact ranges from approximately $2,470 per patient under conservative assumptions to $6,649 per patient under higher capture scenarios. In subsequent years, ongoing value ranges from approximately $1,554 to $4,451 per patient annually, depending on the degree of stability achieved. At scale, these effects compound quickly. In a cohort of 1,000 CRPS patients, the base-case model implies approximately $4.4 million in first-year value and nearly $3.0 million in recurring annual value, even without assuming full remission across the population.

These estimates are intentionally conservative. They do not assume universal response, nor do they assume complete elimination of symptoms. Instead, they quantify the recoverable portion of cost that arises from instability-driven inefficiency, which is the primary target of the CRISPR Remission™ framework. The broader implication is structural. In a state-agnostic model, variability is treated as noise, and cost is managed through repeated escalation of care. In a state-dependent model, variability becomes a measurable and actionable parameter. Intervention is aligned with system readiness, reducing inefficiency and improving durability.

Within this context, CRISPR-based therapies shift from being perceived solely as high-cost interventions to functioning as stabilizing infrastructure. Their value is not defined by upfront expense alone, but by their ability to reduce long-term instability, decrease cumulative utilization, and expand the proportion of patients who achieve sustained improvement. CRISPR Remission™ therefore operates not only as a clinical framework, but as an economic one. By aligning precision intervention with the dynamic biology of CRPS, it enables both improved patient outcomes and measurable system-level savings within the same model.

13. Engineering Stability in CRPS and Neuroimmune Disease

CRPS has long resisted conventional treatment approaches, not because it is untreatable, but because it has been approached through frameworks that do not reflect its underlying biology. Treating CRPS as a static pain condition has led to interventions that suppress symptoms without restoring the system from which those symptoms emerge.

Evidence now supports a different view. CRPS is a condition of multi-system dysregulation, in which neural, immune, and autonomic pathways interact to sustain instability. This instability is dynamic, shifting in response to internal and external factors, and cannot be fully addressed through single-target or static interventions (Birklein & Schlereth, 2015; Bruehl, 2015).

Advances in gene therapy and CRISPR-based technologies have introduced the possibility of sustained biological intervention. Preclinical studies demonstrate that targeted modulation of pain-relevant pathways can produce long-lasting effects, suggesting that durable change is achievable at the molecular level (Moreno et al., 2021; Chen et al., 2024).

However, the application of these technologies must evolve to match the complexity of the conditions they are intended to treat. CRPS requires an approach that accounts for heterogeneity, system interaction, and temporal variability. The CRISPR Remission™ framework addresses this need by integrating phenotype stratification, target class selection, modality choice, and timing into a unified decision architecture. The emergence of gene-editing technologies has shifted the central challenge in complex chronic disease. The limiting factor is no longer simply whether these tools can be built or deployed, but whether they can be applied in a way that reflects the structure and behavior of the system they are intended to influence. In biologically stable, genetically defined conditions, that question may be relatively narrow. In conditions such as CRPS, where neural, immune, and autonomic processes interact dynamically over time, the question becomes substantially more complex.

CRISPR Remission™ is positioned at that point of complexity. Rather than treating gene editing as a stand-alone act of molecular precision, the framework treats it as one component within a broader intervention architecture designed for unstable systems. By integrating phenotype stratification, multi-pathway targeting, and flare-aware timing, CRISPR Remission™ extends precision medicine beyond static genetic correction and toward state-aware, system-integrated intervention. In doing so, it addresses a core limitation of current approaches, which often assume that accurate targeting alone is sufficient even when the disease itself is dynamic.

The purpose of this model is not simply to reduce pain intensity, but to restore the system’s capacity to maintain stability over time. That shift in emphasis carries broader implications, because conditions characterized by neuroimmune instability extend beyond CRPS and include a growing range of chronic and post-infectious disorders. A framework capable of addressing instability in one condition may therefore provide a foundation for intervention across many.

Insights from Project Eve, CYNAERA’s ongoing pilot in autoimmune-menopause flare prediction and undiagnosed condition detection, further demonstrate the practical power of longitudinal symptom journaling. In women navigating hormonal transitions alongside autoimmune and infection-associated conditions, the pilot has repeatedly surfaced predictable flare patterns driven by hormonal phase, environmental load, and masked post-infectious amplification, patterns that standard diagnostic pathways frequently overlook. These real-world findings reinforce the necessity of terrain-aware modeling as we translate CRISPR technologies into volatile, multi-system diseases.

From this perspective, the future of CRPS treatment is unlikely to be defined by stronger suppression or more aggressive intervention alone. It will be defined by the ability to apply precision therapies within a dynamic biological context, aligning intervention with the state of the system rather than imposing it against that system’s underlying behavior. In that context, remission is no longer an abstract clinical aspiration, but an engineering problem that can be approached with increasing precision and structure.

Frequently Asked Questions

Can CRISPR treat Complex Regional Pain Syndrome (CRPS)? CRISPR-based therapies have not yet been approved for Complex Regional Pain Syndrome, or CRPS. However, emerging gene-regulation research suggests that pain-relevant pathways such as NaV1.7, inflammatory signaling, and neuroimmune activation may be modifiable in ways that could support long-term stabilization rather than short-term symptom suppression.

What is CRISPR Remission™ in CRPS? CRISPR Remission™ is a flare-aware, state-dependent framework for applying gene-based intervention in biologically unstable conditions such as CRPS. Rather than treating pain as an isolated symptom, the framework evaluates phenotype, pathway interaction, modality choice, and timing to support more durable system-level improvement.

Why do current CRPS treatments often fail to produce remission? Most CRPS treatments are designed to reduce pain or inflammation without accounting for the fluctuating interaction between nociceptive signaling, immune activity, autonomic dysfunction, and central sensitization. That mismatch can lead to partial improvement without restoring long-term system stability.

How is remission different from analgesia in CRPS? Analgesia reduces pain intensity. Remission aims to restore the system’s ability to maintain stability over time. In CRPS, a patient may experience less pain temporarily while the underlying neuroimmune and autonomic instability remains active. CRISPR Remission™ is designed around the goal of stabilization, not symptom masking alone.

Could gene editing help reduce chronic pain permanently? Gene editing may eventually support longer-lasting relief in some chronic pain conditions by modulating the molecular pathways that sustain pain amplification. In complex conditions such as CRPS, durable benefit will likely depend on matching the intervention to the patient’s biology, disease subtype, and timing of treatment.

Why does timing matter in CRISPR-based intervention for CRPS? CRPS is a dynamic condition with periods of greater and lesser biologic volatility. Intervention during a stabilization window may improve tolerability, reduce rebound risk, and increase durability of response. Timing is therefore treated as part of therapeutic design rather than as a secondary consideration.

Is CRPS only a pain disorder? No. CRPS is better understood as a multi-system condition involving pain signaling, immune activation, autonomic dysfunction, vascular changes, and altered central processing. That is why single-pathway treatment approaches often fall short.

Can CRISPR Remission™ apply beyond CRPS? Yes. The framework is designed for conditions marked by biological instability, fluctuating symptoms, and interacting systems. That includes neuroimmune and post-infectious conditions where treatment success may depend on state-aware timing and multi-pathway strategy.

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.

• Primary Chronic Trigger 

• Mold Exposure as A Flare Catalyst in ME/CFS

• VitalGuard™: Environmental Flare Risk Engine

• Corrected National Prevalence Estimates for (IACCs)

• One New Long COVID Case Every Minute in the United States

• Undercounted from Kabul to Kansas: The Hidden Men of IACC

• The Science of Remission of IACC's

• A Nobel-Scale Advance: AI-Powered CRISPR Platform to End IACC's

• State-Dependent CRISPR Delivery

• Personalized CRISPR Remission™ for Sarcoidosis

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.

References

1. Adinig, C. (2025). A Nobel-Scale Advance: AI-Powered CRISPR Platform to End Infection-Associated Chronic Conditions. CYNAERA.

2. Baron, R., Binder, A., & Wasner, G. (2010). Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology, 9(8), 807–819.

3. Birklein, F., & Dimova, V. (2017). Complex regional pain syndrome: Up-to-date. Pain Reports, 2(6), e624.

4. Birklein, F., & Schlereth, T. (2015). Complex regional pain syndrome: Significant progress in understanding. Pain, 156(Suppl 1), S94–S103.

5. Birklein, F., O’Neill, D., & Schlereth, T. (2018). Complex regional pain syndrome: An optimistic perspective. Neurology, 91(9), 410–418.

6. Bruehl, S. (2015). Complex regional pain syndrome. BMJ, 351, h2730.

7. Chen, Y., Liu, X., Zhang, Y., & Wang, H. (2024). CRISPR-based gene therapy for chronic pain: Mechanisms and translational potential. Molecular Therapy, 32(1), 45–60.

8. Deer, T. R., Mekhail, N., Provenzano, D., Pope, J., Krames, E., Leong, M., Levy, R., Abejon, D., Buchser, E., Burton, A., Caraway, D., Cousins, M., De Andrés, J., Diwan, S., Eldabe, S., Erdek, M., Grigsby, E., Kim, P., & Staats, P. (2017). The appropriate use of neurostimulation for chronic pain and ischemic diseases: The Neuromodulation Appropriateness Consensus Committee. Neuromodulation, 20(2), 96–132.

9. Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236.

10. Elsamadicy, A. A., Yang, S., Sergesketter, A. R., Ashraf, B., Charalambous, L. T., Kemeny, H. R., Xie, J., Lavin, P. J., & Lad, S. P. (2018). Prevalence and cost analysis of complex regional pain syndrome (CRPS): A role for neuromodulation. Neuromodulation, 21(6), 608–614.

11. Fields, H. L. (2018). How expectations influence pain. Pain, 159(Suppl 1), S3–S10.

12. Gannon, B., Finn, D. P., Voon, P., Ryan, A., & O’Gorman, D. (2013). An analysis of a regional pain management service in Ireland: The economic cost of chronic pain. Pain Medicine, 14(10), 1518–1528.

13. Goebel, A., Baranowski, A., Maurer, K., Ghiai, A., & McCabe, C. (2010). Immune responses in complex regional pain syndrome. Annals of Neurology, 68(2), 259–269.

14. Habib, A. M., Wood, J. N., & Cox, J. J. (2023). Gene therapy approaches for pain: Progress and challenges. Nature Reviews Neurology, 19(3), 145–158.

15. Ji, R. R., Nackley, A., Huh, Y., Terrando, N., & Maixner, W. (2018). Neuroinflammation and central sensitization in chronic pain. Nature Reviews Neuroscience, 19(7), 433–447.

16. Kemler, M. A., Barendse, G. A. M., van Kleef, M., de Vet, H. C. W., Rijks, C. P. M., Furnée, C. A., & van den Wildenberg, F. A. J. M. (2000). Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. New England Journal of Medicine, 343(9), 618–624.

17. Latremoliere, A., & Woolf, C. J. (2009). Central sensitization: A generator of pain hypersensitivity by central neural plasticity. The Journal of Pain, 10(9), 895–926.

18. Marinus, J., Moseley, G. L., Birklein, F., Baron, R., Maihöfner, C., Kingery, W. S., & van Hilten, J. J. (2011). Clinical features and pathophysiology of complex regional pain syndrome. The Lancet Neurology, 10(7), 637–648.

19. Moreno, A. M., Aleman, F., Catroli, G. F., Hunt, M., Hu, M., Dailamy, A., Pla, A., Woller, S. A., Palmer, N., & Mali, P. (2021). Long-lasting analgesia via targeted in vivo epigenetic repression of NaV1.7. Science Translational Medicine, 13(584), eaay9056.

20. Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., et al. (2025). Patient-specific in vivo gene editing to treat a rare genetic disease. New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2504747 

21. Rittner, H. L., Brack, A., & Stein, C. (2001). Proinflammatory cytokines in complex regional pain syndrome. Pain, 91(1–2), 1–5.

22. van Velzen, G. A. J., van Hilten, J. J., & van Dijk, J. G. (2019). Genetic factors in complex regional pain syndrome. Pain, 160(7), 1544–1555.

23. Waxman, S. G. (2013). Painful Na-channelopathies: An expanding universe. Trends in Molecular Medicine, 19(7), 406–409.